THE 2019 PIPELINE BY PHASE - Pharma Intelligence€¦ · PRECLINICAL PHASE I PHASE II PHASE III 6%...
1
2 3 4 5 6 7 8 9 10 Pharma R&D ANNUAL REVIEW 2019 THE PIPELINE CONTINUES TO REACH NEW HEIGHTS EACH YEAR TOTAL R&D PIPELINE SIZE, BY YEAR THE 2019 PIPELINE BY PHASE 2018 2019 NOVARTIS TAKEDA JOHNSON & JOHNSON ASTRAZENECA SANOFI ROCHE GLAXOSMITHKLINE MERCK & CO. PFIZER ELI LILLY 219 (223) 211 (164) 208 (216) 194 (205) 192 (179) 189 (191) 177 (191) 176 (191) 163 (192) 124 (121) 131 99 112 111 93 106 99 86 96 74 PHARMA R&D LEADERBOARDS 2001 0 6000 4000 2000 12000 10000 8000 18000 16000 14000 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Source: Pharmaprojects® January 2019 As the 2019 season kicks off, let’s take a look at team morale as we look back at last year’s pharma performance. GROWTH RATE SINCE 2018 5.69% GROWTH RATE OVER THE PAST 3 YEARS 16,181 6% PIPELINE PROJECTS IN 2019 This is a highly respectable performance during a year of ongoing political instability. FUMBLES AT PHASE II STILL HOLDING UP THE FIELD 8040 2127 2360 1006 214 150 1199 52 8520 2281 2576 1009 199 152 1273 60 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 Preclin Phase I Phase II Phase III Pre-reg Registered Launched Suspended Drug count Drug count with 4,001 new drugs debuting in development much more than the 3.0% seen last year following a flat 2018 even worse than 2018’s 1.9% drop PRECLINICAL PHASE I PHASE II PHASE III 6% INCREASE 7.2% INCREASE 9.2% INCREASE 3.6% DECLINE Rather than breaking through the Phase II boundary line, the situation is steadily worsening, with a greater percentage of drugs reaching Phase II having to leave the field. TOP PHARMA COMPANIES BY SIZE OF PIPELINE 1 COMPANY HQ COMPANY NO. OF DRUGS IN PIPELINE 2019 (2018) NO. OF ORIGINATED DRUGS 2019 Novartis narrowly wins the World Series for a third consecutive year. Takeda is the new runner-up in our league this year, thanks to the Shire acquisition. As things stand, without the results of any post-merger pipeline consolidation, Takeda catapults up to number two in the table – the highest position ever reached by a Japanese-headquartered company. 2 3 4 5 6 7 8 9 10 ANTICANCER BIOTECHNOLOGY NEUROLOGICAL ANTI-INFECTIVE ALIMENTARY/METABOLIC REFORMULATIONS MUSCULOSKELETAL DERMATOLOGICAL IMMUNOLOGICAL CARDIOVASCULAR 5697 (5212) 5422 (4751) 2775 (2604) 2270 (2238) 2407 (2237) 2173 (2073) 1611 (1597) 962 (929) 977 (916) 920 (893) TOP THERAPY GROUPS 1 THERAPY GROUP NO. OF ACTIVE DRUGS 2019 (2018) The playing field here is, forever, the same – the dominance of cancer. Cancer’s pre-eminence as a therapeutic target is showing all the signs of becoming as immortal as some cancer cells themselves. Further down the field, Neurologicals (+6.6%) and Alimentary/Metabolics (+7.6%) both knocked it out of the park with higher than average increases, whereas, if you excuse the mixed metaphor, Anti-infectives (+1.4%) and Musculoskeletals (+0.9%) were both well below par. Cancer indications continue to account for seven of the top ten, and all of the top five. Breast cancer pulls further into the lead, with a 6.5% uptick, although runner-up non-small cell lung cancer has a bigger percentage rise (7.7%). Only prostate cancer at number eight and brain cancer at number nine have smaller pipelines this year than last year (the latter only declines by one drug anyway). Away from oncology, Alzheimer’s disease battles on and up the table, but is still searching for that elusive victory. CANCER, BREAST CANCER, LUNG, NON-SMALL CELL CANCER, COLORECTAL CANCER, OVARIAN CANCER, PANCREATIC ALZHEIMER'S DISEASE DIABETES, TYPE 2 CANCER, PROSTATE CANCER, BRAIN CANCER, MELANOMA 2774 (727) 586 (544) 535 (503) 442 (434) 438 (430) 405 (381) 382 (407) 366 (381) 360 (361) 357 (346) ↑ ↑ ↑ ↔ ↔ ↑ ↓ ↓ ↔ ↔ TOP 10 DISEASES / INDICATIONS DISEASE NO. OF ACTIVE DRUGS 2019 (2018) TREND 2 (2) 3 (3) 4 (4) 5 (5) 6 (8) 7 (6) 8 (7) 9 (9) 10 (11) 1 (1) POSITION 2019 (2018) Despite some chronic game-related concerns, the pharma industry teams push forward with some great scores and plenty of points on the board. Click to download the Review today
Transcript of THE 2019 PIPELINE BY PHASE - Pharma Intelligence€¦ · PRECLINICAL PHASE I PHASE II PHASE III 6%...
2
3
4
5
6
7
8
9
10
Pharma R&DANNUAL REVIEW 2019
THE PIPELINE CONTINUES TO REACH NEW HEIGHTS EACH YEAR
TOTAL R&D PIPELINE SIZE, BY YEAR
THE 2019 PIPELINE BY PHASE
2018 2019
NOVARTIS
TAKEDA
JOHNSON & JOHNSON
ASTRAZENECA
SANOFI
ROCHE
GLAXOSMITHKLINE
MERCK & CO.
PFIZER
ELI LILLY
219 (223)
211 (164)
208 (216)
194 (205)
192 (179)
189 (191)
177 (191)
176 (191)
163 (192)
124 (121)
131
99
112
111
93
106
99
86
96
74
PHARMA R&D LEADERBOARDS
20010
6000
4000
2000
12000
10000
8000
18000
16000
14000
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019Source: Pharmaprojects® January 2019
As the 2019 season kicks off, let’s take a look at team morale as we look back at last year’s pharma performance.
GROWTH RATE SINCE 2018
5.69% GROWTH RATE OVERTHE PAST 3 YEARS
16,181
6%
PIPELINE PROJECTS IN 2019
This is a highly respectable performance during a year of ongoing political instability.
FUMBLES AT PHASE II STILL HOLDING UP THE FIELD
8040
2127 23
60
1006
214
150
1199
52
8520
2281 25
76
1009
199
152
1273
60
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Preclin Phase I Phase II Phase III Pre-reg Registered Launched Suspended
Drug
cou
ntDr
ug c
ount
with 4,001 new drugs debuting in
development
much more than the 3.0% seen last year
following a flat 2018 even worse than 2018’s 1.9% drop
PRECLINICAL PHASE I PHASE II PHASE III
6% INCREASE 7.2% INCREASE 9.2% INCREASE 3.6% DECLINE
Rather than breaking through the Phase II boundary line, the situation is steadily worsening, with a greater percentage of drugs reaching Phase II having to leave the field.
TOP PHARMA COMPANIES BY SIZE OF PIPELINE
1
COMPANY HQ COMPANYNO. OF DRUGS IN
PIPELINE 2019 (2018)NO. OF ORIGINATED
DRUGS 2019
Novartis narrowly wins the World Series for a third consecutive year.
Takeda is the new runner-up in our league this year, thanks to the Shire acquisition. As things stand, without the results of any post-merger pipeline consolidation, Takeda catapults up to number two in the table – the highest position ever reached by a Japanese-headquartered company.
2
3
4
5
6
7
8
9
10
ANTICANCER
BIOTECHNOLOGY
NEUROLOGICAL
ANTI-INFECTIVE
ALIMENTARY/METABOLIC
REFORMULATIONS
MUSCULOSKELETAL
DERMATOLOGICAL
IMMUNOLOGICAL
CARDIOVASCULAR
5697 (5212)
5422 (4751)
2775 (2604)
2270 (2238)
2407 (2237)
2173 (2073)
1611 (1597)
962 (929)
977 (916)
920 (893)
TOP THERAPY GROUPS
1
THERAPY GROUPNO. OF ACTIVE
DRUGS 2019 (2018)
The playing field here is, forever, the same – the dominance of cancer. Cancer’s pre-eminence as a therapeutic target is showing all the signs of becoming as immortal as some cancer cells themselves.
Further down the field, Neurologicals (+6.6%) and Alimentary/Metabolics (+7.6%) both knocked it out of the park with higher than average increases, whereas, if you excuse the mixed metaphor, Anti-infectives (+1.4%) and Musculoskeletals (+0.9%) were both well below par.
Cancer indications continue to account for seven of the top ten, and all of the top five.
Breast cancer pulls further into the lead, with a 6.5% uptick, although runner-up non-small cell lung cancer has a bigger percentage rise (7.7%).
Only prostate cancer at number eight and brain cancer at number nine have smaller pipelines this year than last year (the latter only declines by one drug anyway).
Away from oncology, Alzheimer’s disease battles on and up the table, but is still searching for that elusive victory.
CANCER, BREAST
CANCER, LUNG, NON-SMALL CELL
CANCER, COLORECTAL
CANCER, OVARIAN
CANCER, PANCREATIC
ALZHEIMER'S DISEASE
DIABETES, TYPE 2
CANCER, PROSTATE
CANCER, BRAIN
CANCER, MELANOMA
2774 (727)
586 (544)
535 (503)
442 (434)
438 (430)
405 (381)
382 (407)
366 (381)
360 (361)
357 (346)
↑
↑
↑
↔
↔
↑
↓
↓
↔
↔
TOP 10 DISEASES / INDICATIONS
DISEASENO. OF ACTIVE
DRUGS 2019 (2018) TREND
2 (2)
3 (3)
4 (4)
5 (5)
6 (8)
7 (6)
8 (7)
9 (9)
10 (11)
1 (1)
POSITION 2019 (2018)
Despite some chronic game-related concerns, the pharma industry teams push forward with some great scores and plenty of points on the board.
Click to download the Review today
